Swaminathan P. Iyer

14.7k total citations · 2 hit papers
286 papers, 7.4k citations indexed

About

Swaminathan P. Iyer is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Swaminathan P. Iyer has authored 286 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Oncology, 97 papers in Pathology and Forensic Medicine and 78 papers in Genetics. Recurrent topics in Swaminathan P. Iyer's work include Lymphoma Diagnosis and Treatment (94 papers), Chronic Lymphocytic Leukemia Research (75 papers) and CAR-T cell therapy research (43 papers). Swaminathan P. Iyer is often cited by papers focused on Lymphoma Diagnosis and Treatment (94 papers), Chronic Lymphocytic Leukemia Research (75 papers) and CAR-T cell therapy research (43 papers). Swaminathan P. Iyer collaborates with scholars based in United States, France and United Kingdom. Swaminathan P. Iyer's co-authors include Ya Xie, Igor Sokolov, Craig D. Woodworth, Ravi Gaikwad, H. Morkoç̌, Kevin R. Kelly, Venkatesh Subba-Rao, Chang‐Ho Choi, S. F. Fang and H. Zabel and has published in prestigious journals such as Science, Physical Review Letters and Journal of Biological Chemistry.

In The Last Decade

Swaminathan P. Iyer

265 papers receiving 7.2k citations

Hit Papers

Results From a Pivotal, Open-Lab... 1990 2026 2002 2014 2012 1990 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
    2012 485 citations Bertrand Coiffier, Barbara Pro et al. Journal of Clinical Oncology profile →
  2. Gallium arsenide and other compound semiconductors on silicon
    1990 476 citations Swaminathan P. Iyer et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Swaminathan P. Iyer United States 45 2.1k 2.1k 1.9k 1.4k 1.4k 286 7.4k
H. Huber Austria 47 2.2k 1.0× 1.6k 0.8× 501 0.3× 800 0.6× 1.4k 1.0× 308 7.8k
Thomas Fischer Germany 45 1.7k 0.8× 919 0.4× 575 0.3× 1.0k 0.7× 291 0.2× 202 9.1k
Devinder Gill Australia 36 946 0.4× 2.5k 1.2× 2.7k 1.4× 1.4k 1.0× 1.2k 0.8× 145 5.4k
Mark E. Law United States 40 846 0.4× 732 0.3× 1.2k 0.6× 1.0k 0.7× 438 0.3× 280 5.9k
Mario Luppi Italy 46 722 0.3× 3.0k 1.4× 1.1k 0.6× 963 0.7× 733 0.5× 267 6.9k
T. Kinoshita Japan 41 552 0.3× 638 0.3× 754 0.4× 365 0.3× 517 0.4× 324 6.6k
William H. Meyer United States 60 1.7k 0.8× 2.4k 1.2× 2.3k 1.2× 143 0.1× 346 0.3× 252 11.2k
Jason S. Lewis United States 83 4.4k 2.0× 5.9k 2.8× 462 0.2× 644 0.5× 822 0.6× 476 22.3k
Dong‐Wan Kim South Korea 58 4.5k 2.1× 13.9k 6.6× 1.4k 0.7× 727 0.5× 2.3k 1.7× 364 21.5k
Sten Eriksson Sweden 47 1.6k 0.8× 1.7k 0.8× 240 0.1× 502 0.4× 333 0.2× 195 8.6k

Countries citing papers authored by Swaminathan P. Iyer

Since Specialization
Citations

This map shows the geographic impact of Swaminathan P. Iyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Swaminathan P. Iyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Swaminathan P. Iyer more than expected).

Fields of papers citing papers by Swaminathan P. Iyer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Swaminathan P. Iyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Swaminathan P. Iyer. The network helps show where Swaminathan P. Iyer may publish in the future.

Co-authorship network of co-authors of Swaminathan P. Iyer

This figure shows the co-authorship network connecting the top 25 collaborators of Swaminathan P. Iyer. A scholar is included among the top collaborators of Swaminathan P. Iyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Swaminathan P. Iyer. Swaminathan P. Iyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chemaly, Roy F., Ying Jiang, Jeremy Ramdial, et al.. (2025). P-1013. Incidence and Risk Factors for Fungal Infection after CD19-targeted Chimeric Antigen Receptor T cell Therapy for Non-Hodgkin Lymphoma. Open Forum Infectious Diseases. 12(Supplement_1). 1 indexed citations
2.
3.
Li, Meng, Rahul K. Shah, Ruitao Lin, et al.. (2025). Clinical trial success rate in lymphoma: fate of trials and agents from 2000 to 2019. Blood Advances. 10(5). 1713–1721.
4.
Westin, Jason R., Loretta J. Nastoupil, Ranjit Nair, et al.. (2024). Factors associated with manufacturing failure of commercial CD19 CAR-T cell products for large b cell lymphoma (LBCL).. Journal of Clinical Oncology. 42(16_suppl). 7044–7044. 4 indexed citations
5.
Iyer, Swaminathan P., Steven M. Horwitz, Salvia Jain, et al.. (2024). Confirmatory Efficacy and Safety Evaluation of MB-105, a CD5.CAR T Therapy: Multicenter Phase 2 Study in Patients with Relapsed/Refractory T Cell Lymphoma (R/R TCL). Blood. 144(Supplement 1). 7223–7223.
6.
7.
Al‐Juhaishi, Taha, Yingjun Wang, Denái R. Milton, et al.. (2023). Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant. Bone Marrow Transplantation. 58(9). 1000–1007. 3 indexed citations
8.
Khawaja, Fareed, Joseph Sassine, Swaminathan P. Iyer, et al.. (2022). Herpesviruses Infections in CAR T Cell Recipients. Transplantation and Cellular Therapy. 28(3). S381–S382. 3 indexed citations
9.
Lewis, Brian, et al.. (2022). Sustained response to erythropoietin for anemia in NK-cell large granular lymphocytosis: A brief case report. Leukemia Research Reports. 17. 100292–100292.
10.
11.
Huen, Auris, Bradley M. Haverkos, Jasmine M. Zain, et al.. (2020). Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma. Cancers. 12(8). 2293–2293. 55 indexed citations
12.
Mamlouk, Omar, Ranjit Nair, Swaminathan P. Iyer, et al.. (2020). Safety of CAR T-cell therapy in kidney transplant recipients. Blood. 137(18). 2558–2562. 38 indexed citations
13.
14.
Zhao, Nianxi, Jianjun Qi, Zihua Zeng, et al.. (2015). Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia. Biomaterials. 67. 42–51. 97 indexed citations
15.
Fiskus, Warren, Sunil Sharma, Jun Qi, et al.. (2014). Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells. Molecular Cancer Therapeutics. 13(5). 1142–1154. 155 indexed citations
16.
Fiskus, Warren, Sunil Sharma, Jun Qi, et al.. (2014). BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD. Molecular Cancer Therapeutics. 13(10). 2315–2327. 112 indexed citations
17.
Coiffier, Bertrand, Barbara Pro, H. Miles Prince, et al.. (2012). Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy. Journal of Clinical Oncology. 30(6). 631–636. 485 indexed citations breakdown →
18.
Wierda, William G., Thomas J. Kipps, Jan Dürig, et al.. (2011). Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood. 117(24). 6450–6458. 86 indexed citations
19.
Chanan‐Khan, Asher, Kena C. Miller, David Lawrence, et al.. (2010). Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer. 117(10). 2127–2135. 66 indexed citations
20.
Chanan‐Khan, Asher, Kena C. Miller, Laurie Musial, et al.. (2006). Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study. Journal of Clinical Oncology. 24(34). 5343–5349. 314 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H. Huber Breakdown of academic impact, for papers by Thomas Fischer Breakdown of academic impact, for papers by Devinder Gill Breakdown of academic impact, for papers by Mark E. Law Breakdown of academic impact, for papers by Mario Luppi Breakdown of academic impact, for papers by T. Kinoshita Breakdown of academic impact, for papers by William H. Meyer Breakdown of academic impact, for papers by Jason S. Lewis Breakdown of academic impact, for papers by Dong‐Wan Kim Breakdown of academic impact, for papers by Sten Eriksson
Rankless by CCL
2026